Expand MESO Menu
MESO MENU

MESO Latest Press Releases

-- August 26, 2026 --

Mesoblast Reports Substantial Revenue Growth to US$120M Globe Newswire 8:32 PM

-- August 24, 2026 --

Mesoblast Financial Results and Corporate Update Webcast Globe Newswire 7:00 AM

-- August 16, 2026 --

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain Globe Newswire 8:35 PM

-- July 29, 2026 --

Mesoblast Reports Ryoncil Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch Globe Newswire 8:57 PM

-- July 13, 2026 --

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain Globe Newswire 8:35 PM

-- July 9, 2026 --

Ryoncil Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 Globe Newswire 8:30 PM

-- June 30, 2026 --

Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs Globe Newswire 8:38 PM

-- June 24, 2026 --

Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility Globe Newswire 8:59 PM

-- April 29, 2026 --

Mesoblast Reports Ryoncil Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million Globe Newswire 8:55 PM

-- April 28, 2026 --

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Globe Newswire 8:53 PM

-- April 14, 2026 --

Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products Globe Newswire 8:10 PM

-- April 10, 2026 --

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil in Duchenne Muscular Dystrophy - CORRECTION Globe Newswire 4:09 PM

-- April 8, 2026 --

Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation Globe Newswire 9:07 AM

-- April 7, 2026 --

Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil in Duchenne Muscular Dystrophy Globe Newswire 11:35 PM

-- April 6, 2026 --

Ryoncil Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter Globe Newswire 9:03 PM
Market Data Delayed 15 Minutes